Edwards Lifesciences Co. (NYSE:EW) Receives Average Recommendation of “Hold” from Analysts

Edwards Lifesciences Co. (NYSE:EW) has been assigned an average rating of “Hold” from the twenty-six analysts that are currently covering the stock, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $75.67.

Several equities research analysts have recently weighed in on EW shares. Wells Fargo & Company reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Citigroup reduced their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a report on Tuesday, October 1st. Finally, Royal Bank of Canada decreased their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock worth $1,099,238 over the last quarter. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently modified their holdings of EW. Brookstone Capital Management lifted its stake in shares of Edwards Lifesciences by 3.2% during the first quarter. Brookstone Capital Management now owns 12,275 shares of the medical research company’s stock worth $1,173,000 after buying an additional 383 shares during the period. Citizens Business Bank purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $3,275,000. Chapin Davis Inc. increased its holdings in shares of Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after purchasing an additional 140 shares during the period. Aviance Capital Partners LLC raised its stake in shares of Edwards Lifesciences by 61.8% in the first quarter. Aviance Capital Partners LLC now owns 7,194 shares of the medical research company’s stock worth $687,000 after purchasing an additional 2,748 shares during the last quarter. Finally, Miracle Mile Advisors LLC raised its stake in shares of Edwards Lifesciences by 16.1% in the first quarter. Miracle Mile Advisors LLC now owns 10,878 shares of the medical research company’s stock worth $1,040,000 after purchasing an additional 1,507 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.8 %

Shares of NYSE EW opened at $67.54 on Friday. The stock has a market capitalization of $40.69 billion, a price-to-earnings ratio of 9.75, a P/E/G ratio of 3.86 and a beta of 1.13. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm’s 50-day moving average price is $67.92 and its 200-day moving average price is $77.69.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.